Kazazian Asset Management LLC raised its stake in Clovis Oncology Inc (NASDAQ:CLVS) by 11.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,517 shares of the biopharmaceutical company’s stock after acquiring an additional 2,024 shares during the quarter. Clovis Oncology makes up 1.4% of Kazazian Asset Management LLC’s portfolio, making the stock its 20th biggest holding. Kazazian Asset Management LLC’s holdings in Clovis Oncology were worth $1,327,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CLVS. Cypress Capital Management LLC WY increased its stake in Clovis Oncology by 272.7% in the third quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 1,500 shares during the last quarter. Commonwealth Equity Services Inc acquired a new position in Clovis Oncology in the third quarter valued at $239,000. First Republic Investment Management Inc. acquired a new position in Clovis Oncology in the third quarter valued at $251,000. BB&T Securities LLC acquired a new position in Clovis Oncology in the third quarter valued at $288,000. Finally, Greenwood Capital Associates LLC increased its stake in Clovis Oncology by 21.6% in the fourth quarter. Greenwood Capital Associates LLC now owns 5,605 shares of the biopharmaceutical company’s stock valued at $381,000 after purchasing an additional 996 shares during the last quarter.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $54.09, for a total value of $162,270.00. Following the completion of the sale, the insider now owns 180,571 shares of the company’s stock, valued at $9,767,085.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Thorlef Spickschen sold 4,500 shares of the company’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $64.97, for a total value of $292,365.00. Following the completion of the sale, the director now directly owns 21,118 shares of the company’s stock, valued at approximately $1,372,036.46. The disclosure for this sale can be found here. Insiders sold 19,500 shares of company stock valued at $1,178,730 in the last ninety days. Company insiders own 12.50% of the company’s stock.
Shares of Clovis Oncology Inc (CLVS) opened at $59.03 on Friday. Clovis Oncology Inc has a 1 year low of $45.42 and a 1 year high of $99.45. The company has a quick ratio of 7.35, a current ratio of 7.69 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $3,014.16, a PE ratio of -7.88 and a beta of 1.10.
Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Monday, February 26th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.29) by $0.25. Clovis Oncology had a negative return on equity of 81.34% and a negative net margin of 624.02%. The company had revenue of $17.04 million during the quarter, compared to the consensus estimate of $19.42 million. During the same quarter in the prior year, the business earned ($1.83) earnings per share. The company’s revenue was up 21746.2% compared to the same quarter last year. research analysts expect that Clovis Oncology Inc will post -4.75 EPS for the current fiscal year.
Several research firms recently commented on CLVS. ValuEngine upgraded Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Oppenheimer reissued a “hold” rating on shares of Clovis Oncology in a research report on Wednesday, December 20th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Clovis Oncology in a research report on Thursday, January 11th. BidaskClub raised Clovis Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 9th. Finally, Zacks Investment Research downgraded Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $87.84.
ILLEGAL ACTIVITY NOTICE: “Kazazian Asset Management LLC Has $1.33 Million Stake in Clovis Oncology Inc (CLVS)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/03/16/kazazian-asset-management-llc-has-1-33-million-stake-in-clovis-oncology-inc-clvs.html.
Clovis Oncology Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.